Want to see SE:BICO full AI Analyst Report?
BICO Stock Chart & Stats
kr18.16
-kr2.08(-4.75%)
At close: 4:00 PM EST
kr18.16
-kr2.08(-4.75%)
Day’s Range― - ―
52-Week Rangekr12.94 - kr42.46
Previous CloseN/A
Volume245.45K
Average Volume (3M)288.59K
Market Cap
kr999.34M
Enterprise Valuekr1.12K
Total Cash (Recent Filing)kr744.30M
Total Debt (Recent Filing)kr690.60M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Aug 19, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.97
Shares Outstanding69,074,900
10 Day Avg. Volume264,488
30 Day Avg. Volume288,586
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.99
P/FCF Ratio26.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.9
Revenue Forecast (FY)kr1.57B
Bulls Say, Bears Say
Bulls Say
Improving Gross Margin & Positive Operating Cash FlowAn improved gross margin increases per-unit economics for instruments and consumables, and positive operating cash flow indicates the business can presently fund operations internally. Together these durable improvements support margin recovery and reduce near-term external funding needs.
Recurring Revenue Model From Instruments, Consumables, Software, ServicesSelling capital equipment that creates an installed base plus consumables, software and service contracts builds sticky, recurring revenue. This business model supports long-term revenue visibility and cross-sell opportunities across research and pharma customers.
Moderate Leverage; Debt Below EquityA debt-to-equity around 0.86 is a moderate leverage level that limits refinancing strain relative to highly leveraged peers. This structural balance provides some capacity to invest in product development or commercialization if operating performance stabilizes.
Bears Say
Deep, Recurring Losses And Very Negative Net MarginA persistent, very large negative net margin erodes equity and makes it difficult to invest in growth or R&D without external capital. Sustained losses increase fundraising risk and can constrain long-term competitiveness if profit recovery is not achieved.
Material Revenue Declines And VolatilitySubstantial and volatile revenue trends weaken the installed-base growth that drives recurring consumables and services. This undermines predictability of future cash flows, complicates scaling and cross-sell plans, and raises execution risk for returning to stable growth.
Deteriorating Free Cash Flow And Inconsistent Cash GenerationA large drop in free cash flow and historical inconsistency reduce the company's ability to self-fund capex, commercial expansion and R&D. This increases reliance on external financing and heightens risk if profitability does not sustainably improve.
BICO Group AB Class B News
BICO FAQ
What was BICO Group AB Class B’s price range in the past 12 months?
BICO Group AB Class B lowest stock price was kr12.94 and its highest was kr42.46 in the past 12 months.
What is BICO Group AB Class B’s market cap?
BICO Group AB Class B’s market cap is kr999.34M.
When is BICO Group AB Class B’s upcoming earnings report date?
BICO Group AB Class B’s upcoming earnings report date is Aug 19, 2026 which is in 32 days.
How were BICO Group AB Class B’s earnings last quarter?
BICO Group AB Class B released its earnings results on Apr 29, 2026. The company reported -kr1.725 earnings per share for the quarter, missing the consensus estimate of -kr1 by -kr0.725.
Is BICO Group AB Class B overvalued?
According to Wall Street analysts BICO Group AB Class B’s price is currently Overvalued.
Does BICO Group AB Class B pay dividends?
BICO Group AB Class B does not currently pay dividends.
What is BICO Group AB Class B’s EPS estimate?
BICO Group AB Class B’s EPS estimate is -0.75.
How many shares outstanding does BICO Group AB Class B have?
BICO Group AB Class B has 69,074,900 shares outstanding.
What happened to BICO Group AB Class B’s price movement after its last earnings report?
BICO Group AB Class B reported an EPS of -kr1.725 in its last earnings report, missing expectations of -kr1. Following the earnings report the stock price went up 9.989%.
Which hedge fund is a major shareholder of BICO Group AB Class B?
Currently, no hedge funds are holding shares in SE:BICO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BICO Group AB Class B
BICO Group AB (publ) is a global bio-convergence enterprise, extending its operations across North America, Europe, Asia, and other international markets. Its business is segmented into two primary divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions division equips researchers with advanced tools like 3D bioprinters, hybrid microscopes, and instruments for single-cell dispensing and liquid handling. It also supplies essential consumables such as bioinks, reagents, microscope lenses, and specialized software, alongside 3D reconstructed human tissues crucial for regulatory testing. Furthermore, this segment provides specialized services in 3D cell culture, tissue imaging, multiplex imaging, and digital pathology, primarily benefiting pharmaceutical and biotechnology firms. Conversely, the Bioautomation segment caters to industrial clients with precision dispensing and biosensor technologies, while also delivering diagnostic automation and sophisticated robotics solutions to the medical and diagnostics sectors. Beyond these segments, BICO Group's comprehensive portfolio includes solutions for tissue engineering, multi-omics, cell line development, and diagnostics, contributing to a robust industrial ecosystem. Its principal clientele spans the medical, pharmaceutical, and cosmetic industries. Originally established in 2016 as Cellink AB (publ), the company adopted its current name, BICO Group AB (publ), in August 2021. Its headquarters are located in Gothenburg, Sweden.
Technical Analysis
CellaVision AB
―
Senzime AB
―
Bactiguard Holding AB
―
C-Rad AB Class B
―
Sedana Medical AB
―